Evidence map›Paper›PMID 39115713›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

[

Hendrea Sanne Aletta Tingen, Dion Groothof, Alwin Tubben, Johan Bijzet, Ewout J Houwerzijl, Friso L H Muntinghe, Paul A van der Zwaag, Peter van der Meer, Bouke P C Hazenberg, Riemer H J A Slart and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Impact of disease-modifying therapy on [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hendrea Sanne Aletta TingenDepartment of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands. h.s.a.tingen@umcg.nl.ORCID 0000-0002-8572-9428
Dion GroothofDepartment of Internal Medicine, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.ORCID 0000-0002-1886-4451
Alwin TubbenDepartment of Cardiology, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.ORCID 0000-0001-8414-958X
Johan BijzetDepartment of Laboratory Medicine, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.ORCID 0000-0002-0375-4460
Ewout J HouwerzijlDepartment of Internal Medicine, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
Friso L H MuntingheDepartment of Internal Medicine, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.
Paul A van der ZwaagDepartment of Clinical Genetics, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.ORCID 0000-0001-6693-0321
Peter van der MeerDepartment of Cardiology, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.ORCID 0000-0002-9705-4413
Bouke P C HazenbergDepartment of Rheumatology & Clinical Immunology, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.ORCID 0000-0003-1827-0482
Riemer H J A SlartDepartment of Nuclear Medicine and Molecular Imaging, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.ORCID 0000-0002-5565-1164
Hans L A NienhuisDepartment of Internal Medicine, Groningen Amyloidosis Center of Expertise, University Medical Center Groningen, Hanzeplein 1, 9713GZ, Groningen, The Netherlands.ORCID 0000-0003-3974-6830

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeBone scintigraphy is key to non-invasively diagnosing wild-type transthyretin (ATTRwt) amyloidosis, and is mainly used to assess cardiac radiotracer uptake. However, extracardiac radiotracer uptake is also observed. We investigated whether intensity of soft tissue radiotracer uptake is associated with amyloid load in subcutaneous abdominal fat tissue and with mortality.

methodsThis prospective cohort study included 94 ATTRwt amyloidosis patients and 26 amyloid-negative heart failure controls who underwent whole-body [

resultsATTRwt amyloidosis patients had higher soft tissue-to-rib, heart-to-rib and heart-to-whole body ratios compared with controls. The intensity of soft tissue uptake was positively associated with amyloid load in fat tissue in ATTRwt amyloidosis patients. Estimated glomerular filtration rate, N-terminal brain natriuretic propeptide, high-sensitivity cardiac troponin T (hs-cTnT), and the prognostic Mayo and NAC staging system were associated with all-cause mortality in univariable models. Soft tissue/rib ratio, hs-cTnT and the prognostic staging systems were the only two variables that were independently associated withall-cause mortality.

conclusionSoft tissue radiotracer uptake on bone scintigraphy in ATTRwt amyloidosis patients is positively associated with amyloid load in abdominal fat tissue and is independently associated with mortality.

Indexed as

Amyloid Neuropathies, FamilialAbdominal FatAgedAged, 80 and overAmyloidBiological TransportCase-Control StudiesDiphosphonatesFemaleHumansMaleMiddle AgedOrganotechnetium CompoundsPrealbuminProspective StudiesRadionuclide ImagingAmyloidDiphosphonatesOrganotechnetium CompoundsPrealbumintechnetium 99m hydroxyethylene-diphosphonateATTRBone scintigraphyCardiac amyloidosisExtracardiacSurvival

Identifiers

PMID39115713
PMCPMC11599362

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.